Protalix BioTherapeutics (PLX) Other Working Capital Changes (2010 - 2018)

Protalix BioTherapeutics' Other Working Capital Changes history runs 8 years deep, the most recent figure standing at $1.7 million for Q2 2024.

• On a quarterly basis, Other Working Capital Changes rose 114.05% year-over-year to $1.7 million in Q2 2024; TTM through Jun 2024 was $12.7 million, a 171.74% increase from a year earlier, with the FY2023 full-year figure at -$13.2 million, down 84.0% from the prior year.
• Other Working Capital Changes fell to $1.7 million in Q2 2024 per PLX's latest filing, from $11.0 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $29.9 million in Q3 2018 and bottomed at -$2.9 million in Q1 2014.
• The 5-year median for Other Working Capital Changes is $60500.0 (2015), against an average of $4.1 million.
• Biggest YoY gain for Other Working Capital Changes was 43141.67% in 2020; the steepest drop was 1372.48% in 2020.
• Year by year, Other Working Capital Changes stood at -$25.7 million in 2020, then soared by 45.63% to -$14.0 million in 2021, then surged by 88.46% to -$1.6 million in 2022, then tumbled by 630.03% to -$11.8 million in 2023, then soared by 114.05% to $1.7 million in 2024.
• Per Business Quant, the three latest PLX Other Working Capital Changes figures stand at $1.7 million (Q2 2024), $11.0 million (Q1 2024), and -$11.8 million (Q2 2023).